Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept
- PMID: 24927994
- DOI: 10.1016/j.ejphar.2014.05.056
Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept
Abstract
Effective and safe pharmacological management of cardiac arrhythmia still constitutes a major clinical challenge. Outward potassium currents mediated by two-pore-domain potassium (K2P) channels promote repolarization of excitable cells. In the heart, inhibition or genetic inactivation of K2P currents results in action potential prolongation. Human K2P3.1 (TASK-1) channels are predominantly expressed in the atria and represent targets for the treatment of atrial fibrillation. In addition, stretch-sensitive K2P2.1 (TREK-1) channels are implicated in mechanoelectrical feedback and arrhythmogenesis in atrial and ventricular tissue. K2P current inhibition by clinically used antiarrhythmic drugs indicates a role of the channels as potential drug targets. This work summarizes the current knowledge on function, pharmacology, and significance of cardiac K2P channels. Therapeutic implications with emphasis on atrial fibrillation are highlighted.
Keywords: Action potential; Antiarrhythmic drug; Atrial fibrillation; Cardiac arrhythmia; K(2P) channel.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
[Cardiac two-pore-domain potassium channels (K2P): Physiology, pharmacology, and therapeutic potential].Dtsch Med Wochenschr. 2012 Aug;137(33):1654-8. doi: 10.1055/s-0032-1305216. Epub 2012 Aug 8. Dtsch Med Wochenschr. 2012. PMID: 22875694 Review. German.
-
Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.Eur J Pharmacol. 2014 Feb 5;724:51-7. doi: 10.1016/j.ejphar.2013.12.030. Epub 2013 Dec 27. Eur J Pharmacol. 2014. PMID: 24374008
-
Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.Eur J Pharmacol. 2013 Dec 5;721(1-3):237-48. doi: 10.1016/j.ejphar.2013.09.029. Epub 2013 Sep 23. Eur J Pharmacol. 2013. PMID: 24070813
-
Atrial-selective K+ channel blockers: potential antiarrhythmic drugs in atrial fibrillation?Can J Physiol Pharmacol. 2017 Nov;95(11):1313-1318. doi: 10.1139/cjpp-2017-0024. Epub 2017 Jul 24. Can J Physiol Pharmacol. 2017. PMID: 28738160 Review.
-
Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model.Life Sci. 2014 Mar 3;97(2):107-15. doi: 10.1016/j.lfs.2013.12.006. Epub 2013 Dec 15. Life Sci. 2014. PMID: 24345461
Cited by
-
Two-pore domain potassium channels enable action potential generation in the absence of voltage-gated potassium channels.Pflugers Arch. 2015 May;467(5):989-99. doi: 10.1007/s00424-014-1660-6. Epub 2014 Dec 9. Pflugers Arch. 2015. PMID: 25482670 Free PMC article. Review.
-
Report on the Ion Channel Symposium : Organized by the German Cardiac Society Working Group on Cellular Electrophysiology (AG 18).Herzschrittmacherther Elektrophysiol. 2018 Mar;29(1):4-13. doi: 10.1007/s00399-017-0549-4. Epub 2018 Jan 8. Herzschrittmacherther Elektrophysiol. 2018. PMID: 29313139 Review. English.
-
Involvement of TREK-1 Channel in Cell Viability of H9c2 Rat Cardiomyoblasts Affected by Bupivacaine and Lipid Emulsion.Cells. 2019 May 14;8(5):454. doi: 10.3390/cells8050454. Cells. 2019. PMID: 31091801 Free PMC article.
-
Voltage-gated and stretch-activated potassium channels in the human heart : Pathophysiological and clinical significance.Herzschrittmacherther Elektrophysiol. 2018 Mar;29(1):36-42. doi: 10.1007/s00399-017-0541-z. Epub 2018 Jan 5. Herzschrittmacherther Elektrophysiol. 2018. PMID: 29305705 Review. English.
-
Monoterpenes Differently Regulate Acid-Sensitive and Mechano-Gated K2P Channels.Front Pharmacol. 2020 May 20;11:704. doi: 10.3389/fphar.2020.00704. eCollection 2020. Front Pharmacol. 2020. PMID: 32508645 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
